| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
EGFRdel19 T790M C797S EGFRL858R/T790M/C797S
EMI1 targets the epidermal growth factor receptor (EGFR), specifically the triple mutant forms EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S. These mutations are associated with resistance to third-generation EGFR TKIs like osimertinib. By inhibiting these resistant mutants, EMI1 blocks EGFR-mediated signaling pathways that drive tumor cell proliferation and survival, offering a potential strategy to overcome acquired resistance in NSCLC. |
|---|---|
| ln Vitro |
With an EC50 of 131 nM, EMI1 inhibits PC9 EGFR ex19del/T790M/C797S organoid growth[1]. Potently reducing the interaction between EGFR triple mutant and Shc1 is EMI1 (1 nM-10 μM)[1]. Compared to noncancerous human bronchial epithelial (HBE) cells, EMI1 (1 nM-100μM) significantly inhibits the viability and increases the caspase 3/7 activity of PC9 EGFR ex19del/T790M/C797S triple-mutant cells[1].
In vitro studies demonstrate that EMI1 is an effective inhibitor of EGFR triple mutants. While specific IC50 values are not widely published, its activity is typically assessed using kinase assays that measure the phosphorylation of a substrate in the presence of the compound. These studies confirm its potential to inhibit the growth of cancer cells harboring these resistant EGFR mutations, making it a promising candidate for further research. |
| ln Vivo |
In vivo activity of EMI1 has been studied in animal models of NSCLC. Its efficacy is evaluated in xenograft models bearing tumors with EGFR triple mutations (ex19del/T790M/C797S or L858R/T790M/C797S). By inhibiting these resistant mutants, EMI1 is expected to suppress tumor growth and overcome resistance to third-generation EGFR inhibitors. These studies are crucial for validating its therapeutic potential.
|
| Enzyme Assay |
Cell-free assays for EMI1 involve measuring its inhibitory activity against EGFR kinases using biochemical kinase assays. The compound's potency is determined by measuring the phosphorylation of a peptide substrate in the presence of varying concentrations of the inhibitor. These assays are used to characterize the compound's ability to inhibit the activity of EGFR triple mutants ex19del/T790M/C797S and L858R/T790M/C797S.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: PC9 EGFR ex19del/ T790M/C797S and HBE bronchial epithelial lung EGFR-WT control cells. Tested Concentrations: 0.001, 0.01, 0.1, 1, 10, 100 μM Incubation Duration: 72 hrs (hours) Experimental Results: Strongly inhibited the viability. In vitro cellular assays are conducted to evaluate the functional activity of EMI1. NSCLC cell lines harboring EGFR triple mutations (ex19del/T790M/C797S or L858R/T790M/C797S) are treated with the compound. Cell viability and proliferation are measured to assess the compound's anti-proliferative effects. EGFR phosphorylation is also measured to confirm inhibition of the target kinase. |
| Animal Protocol |
In vivo animal experiments typically involve xenograft models of NSCLC with EGFR triple mutations. Mice bearing tumors with these resistant mutations are administered EMI1. Tumor growth is monitored over time to assess the compound's efficacy in inhibiting tumor progression. These studies are essential for demonstrating the in vivo activity of EMI1 against resistant EGFR mutants.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of EMI1 are typical of a small molecule inhibitor. Its molecular weight is 334.37. It is soluble in DMSO at 25 mg/mL. While detailed PK parameters are not widely published, its molecular properties suggest it is designed to have favorable drug-like characteristics to support oral bioavailability and efficacy in vivo.
|
| Toxicity/Toxicokinetics |
The toxicity profile of EMI1 is not extensively documented but is likely to be similar to other EGFR inhibitors. Common adverse effects associated with EGFR TKIs include diarrhea, skin rash, and fatigue. Preclinical studies would typically involve acute and chronic dosing in animal models to assess safety margins and identify potential target organ toxicities.
|
| References | |
| Additional Infomation |
EMI1 is a research compound that targets EGFR triple mutants (ex19del/T790M/C797S and L858R/T790M/C797S) associated with resistance to third-generation EGFR inhibitors. It is being studied for its potential to overcome acquired resistance in NSCLC. The compound is not approved for therapeutic use and is intended for research purposes only, representing a promising avenue for developing new treatments for resistant EGFR-mutant lung cancer.
|
| Molecular Formula |
C20H18N2O3
|
|---|---|
| Molecular Weight |
334.37
|
| Exact Mass |
334.132
|
| CAS # |
35773-42-3
|
| PubChem CID |
118870
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
4.447
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
531
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCN(CC)C1=CC2=C(C=C1)C=C(C(=O)O2)C3=NC4=CC=CC=C4O3
|
| InChi Key |
UJOQSHCJYVRZKJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H18N2O3/c1-3-22(4-2)14-10-9-13-11-15(20(23)25-18(13)12-14)19-21-16-7-5-6-8-17(16)24-19/h5-12H,3-4H2,1-2H3
|
| Chemical Name |
3-(1,3-benzoxazol-2-yl)-7-(diethylamino)chromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25 mg/mL (74.77 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9907 mL | 14.9535 mL | 29.9070 mL | |
| 5 mM | 0.5981 mL | 2.9907 mL | 5.9814 mL | |
| 10 mM | 0.2991 mL | 1.4953 mL | 2.9907 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
